Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 26

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 26
---
 Form 8-K regarding an amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics by posting such information on our website at the website address and location specified above.

Insider Trading Policy

We haveadoptedinsider trading policies and procedures governing the purchase, sale and other dispositions of our securities by directors, officers and employees that are designed to promote compliance with insider trading laws, rules and regulations, and applicable Nasdaq listing standards, as well as procedures designed to further the foregoing purposes. A copy of our insider trading policy is filed with our Annual Report on Form 10-K as Exhibit 19.1.

<div align='center'>13</div>

EXECUTIVE O FFICERS The following table sets forth information regarding our executive officers as of April 1, 2025:

| Name                 | ﻿ | Position(s)                                        |     | Age |
| Eric Easom           | ﻿ | President, Chief Executive Officer and Board Chair |     |  57 |
| Lucy Day             | ﻿ | Chief Financial Officer                            |     |  66 |
| Sanjay Chanda, Ph.D. | ﻿ | Chief Development Officer                          |     |  60 |
| Joshua Eizen         | ﻿ | Chief Legal Officer and Chief Operating Officer    |     |  47 |
| Stephen Prior, Ph.D. | ﻿ | Chief Strategy Officer                             |     |  67 |

Information regarding Mr. Easom, who also serves as a director, is set forth above under “Directors and Corporate Governance.” Lucy Day has served as our Chief Financial Officer since November 2019 and as our principal accounting officer since September 2023. From March 2002 to August 2016, Ms. Day served in various financial and administrative roles, including as the initial Chief Financial Officer, Vice President of Finance, and Vice President, Human Resources and Finance at Anacor. Ms. Day has previous experience at Centaur Pharmaceuticals, Inc., a biopharmaceutical company, including as Chief Financial Officer, Bank of America, Sohio Petroleum Company, and Ernst and Young LLP. Ms. Day received a B.A. in Political Economies from the University of California, Berkeley and is a CPA (inactive) in California. Sanjay Chanda, Ph.D., has served as our Chief Development Officer since November 2019. From October 2017 to November 2019, Dr. Chanda provided expert advice related to drug development through Sanjay Chanda Consulting Services